Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Vistagen Therapeutics Inc.

VistaGen Therapeutics ( ($VTGN) ) has shared an update. On November 3, 2025, Vistagen Therapeutics announced the completion of the patient particip...

VistaGen Completes Patient Phase in Key Clinical Trial

William Blair analyst Myles Minter reiterated a Buy rating on VistaGen Therapeutics on November 1. The company’s shares closed last Friday at $3.94...

William Blair Remains a Buy on VistaGen Therapeutics (VTGN)

As we move into the final stretch of the year, stocks continue to grind higher, with the S&P 500 now up 16% year-to-date. Once again, it’s Big Tech...

Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks

The latest announcement is out from VistaGen Therapeutics ( ($VTGN) ). On October 27, 2025, Vistagen Therapeutics appointed Paul R. Edick to its Bo...

Current Quarter	$-0.32	Next Quarter	$-0.34
Current Year	$-1.56	Next Year	$-1.71
QoQ Growth	-6.3%	YoY Growth	-9.6%
3Y EPS CAGR	+39.4%	Target Price	$13.00
Consensus	Buy	Upside	+183.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VTGN	$4.59	+3.15%	527.73K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VTGN	$4.59	+3.1%	527.73K
3
4
5
6

VTGN

VTGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Vistagen Therapeutics Inc. Data in Excel

Get Vistagen Therapeutics Inc. Data in Excel